December
- December 20, 2010
Astellas and AstraZeneca agreed upon an extension of their existing license for Seroquel,to include SeroquelⓇ extended release Tab in Japan
- December 10, 2010
Astellas Pharma Inc. to Promote Employment of Differently Abled People
- December 8, 2010
Astellas Pharma Enters Strategic Equity Deal with Cytori ; To Purchase $10 Million in Equity at $7.00 per Share (pdf 137KB)
- December 6, 2010
Marketing Collaboration on Protopic® Ointment for Treatment of Atopic Dermatitis in Japan
- December 3, 2010
Astellas Pharma Inc. Announce Result of Changing Tomorrow DayTo Support Action in Worldwide Local Communities -Part6- (pdf146 KB)
- December 2, 2010
OSI Pharmaceuticals, Inc. Exercises Option under Discovery and Translational Research Collaboration with AVEO (pdf 42KB)
- December 1, 2010
Astellas Pharma Inc.: Marking 15th Anniversary Donation from Employee-Run Social Contribution Fund, "Flying Star Fund" (pdf 208KB)
November
- November 30, 2010
Presentation Material of Press Conference on 29th November,2010 (pdf2.3 MB)
- November 24, 2010
Astellas Pharma Inc. decided the new corporate name of Merged Production Subsidiary in Japan
- November 16, 2010
Astellas Pharma Inc. and NITE: Search for Microorganisms Overseas in Accordance with the Principles of the Convention on Biological DiversityIndustry-Government Collaborative Research Program (pdf 187KB)
- November 16, 2010
Astellas Pharma Inc. Announce Changing Tomorrow Day To Support Action in European Local Communities -Part5- (pdf 277 KB)
- November 1, 2010
Astellas Pharma Inc.: FY2010-FY2014 Mid -Term Management Plan-Revised Target on Sales and Operating Income in Fiscal Year 2014-(pdf60 KB)
- November 1, 2010
Astellas Pharma Inc.: Enter into Option Agreement with Alavita to Acquire Diannexin Assets
October
- October 28, 2010
Astellas Pharma Inc.: Submits Application for Marketing Approval of Degarelix, an GnRH Antagonist for Prostate Cancer Treatment, in Japan
- October 28, 2010
Astellas Pharma Inc. Files Lawsuit Against Nycomed For Patent Infringement In The United States
- October 27, 2010
Astellas Obtained Approval for Vesicare OD in Japan (pdf 59KB)
- October 26, 2010
Astellas to Merge the Production Subsidiaries in Japan (pdf48 KB)
- October 26, 2010
Astellas Announce Changing Tomorrow Day To Support Action in Asian Local Communities - Part4 - (pdf260 KB)
- October 25, 2010
Astellas Pharma Inc.: Donation of Six Wheelchair Vans by Employee-Run Social Contribution Fund "Flying Star Fund"
- October 19, 2010
Astellas and ASKA Enter into License Agreement for AKP-002 (pdf 64KB)
- October 18, 2010
Transfer of Manufacturing and Marketing Approval and Distribution Rights for the Anti-Allergic Drug "Intal®" (pdf 86KB)
- October 18, 2010
Astellas Pharma Inc. Announces Changing Tomorrow Day To Support Action in Local Communities -Part3- (pdf174 KB)
- October 5, 2010
Micamlo® Combination Tablets AP (new product) and Micardis® Tablets 80 mg are launched on 7 October - Offer new options for effective antihypertensive treatment-(pdf137 KB)
September
- September 30, 2010
Astellas and UMN Pharma enter into the definitive agreement for UMN Pharma's Cell Culture Based Influenza Vaccine Programs in Japan
- September 29, 2010
Astellas Pharma Inc.: Submits Application for Marketing Approval of Darexaban (YM150), an Oral Direct Factor Xa Inhibitor, in Japan
- September 29, 2010
Announcement of the NDA submission of Z-338 /YM443 for functional dyspepsia in Japan
- September 29, 2010
Astellas Pharma US, Inc. Announces Changing Tomorrow Day To Support Action in Local Communities -Part2- (pdf132 KB)
- September 17, 2010
Micamlo® Combination Tablets AP Drug Price Listing (pdf108 KB)
- September 10, 2010
Application for RECALBON® Tablets 50mg/ Bonoteo® Tablets 50mg, A Monthly Oral Osteoporosis Treatment in Japan
- September 8, 2010
Astellas Announces Changing Tomorrow Day To Support Action in Local Communities-Part1- (pdf164 KB)
- September 8, 2010
Donation of Ambulances on First-Aid Day (September 9)
August
- August 17, 2010
Memorandum of Understandings for UMN Pharma's Cell Culture Based Influenza Vaccine Programs in Japan (pdf39 KB)
July
- July 28, 2010
Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology through 2023 (pdf 56KB)
- July 23, 2010
Approval for Micamlo Combination Tablets AP Manufacturing and Distribution(pdf98 KB)
- July 8, 2010
Contents of Stock Acquisition Rights(Stock Option Scheme as Stock-Linked Compensation Plan)(pdf34 KB)
- July 2, 2010
Astellas Nominates President of OSI Pharmaceuticals, Inc. (pdf34 KB)
June
- June 28, 2010
Astellas and Teva Reached a Settlement Agreement on VESIcare® Patent Case
- June 28, 2010
Astellas Announces Oral Presentation of SGLT2 Inhibitor Detailing Safety and Efficacy in Patients with Type 2 Diabetes at the American Diabetes Association Meeting(pdf40 KB)
- June 23, 2010
Allotment of Stock Acquisition Rights (pdf76 KB)
- June 18, 2010
Application for Mirabegron (YM178), a Treatment for OAB, in Japan (pdf42 KB)
- June 15, 2010
Astellas' Brazilian Affiliate Initiates Business Operations(pdf38 KB)
- June 14, 2010
Safety of telmisartan affirmed with an analysis of 50,000 patients(pdf38 KB)
- June 9, 2010
Astellas Completes Acquisition of OSI Pharmaceuticals (pdf32 KB)
- June 8, 2010
Astellas Announces Successful Completion of Tender Offer for Shares of OSI (pdf32 KB)
- June 3, 2010
Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period (pdf42 KB)
May
- May 25, 2010
Announcement of New Mid-Term Management Plan(pdf1.2 MB)
- May 24, 2010
New Contracts Concerning telmisartan (Micardis® Family) Have Been Concluded (pdf73 KB)
- May 18, 2010
Expiration Date of OSI Offer Extended to June 2, 2010 (pdf40 KB)
- May 17, 2010
Presentation Material for Acquisition of OSI Pharmaceuticals, Inc.(PDF343 KB)
- May 17, 2010
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
- May 12, 2010
Astellas Announces Cancellation of Treasury Stock
- May 12, 2010
Partial Amendments to the Articles of Incorporation (pdf 37KB)
- May 12, 2010
Issuance of Stock Acquisition Rights for Stock Option Scheme as Stock-Linked Compensation Plan (pdf 62KB)
April
- April 28, 2010
Astellas Pharma US, Inc. Announces Construction of New Corporate Headquarters
- April 28, 2010
Astellas to Support Relief Efforts following China Chinghai Earthquake (pdf33 KB)
- April 26, 2010
Astellas Nominates Directors(pdf34 KB)
- April 23, 2010
Expiration Date of OSI Offer Extended to May 17, 2010 (pdf40 KB)
- April 16, 2010
Medivation And Astellas Announce Publication in The LANCET of Positive Efficacy Data from Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients(pdf78 KB)
- April 12, 2010
Astellas introduces 'Prograf®' in India (pdf32 KB)
- April 1, 2010
Teijin Pharma and Astellas Pharma Enter into Agreement for Marketing Rights of TMX-67 in China and Hong Kong (pdf54 KB)
March
- March 31, 2010
Expiration Date of OSI Offer Extended to April 23, 2010(pdf61 KB)
- March 30, 2010
Astellas Signs Confidentiality Agreement with OSI(pdf 51KB)
- March 23, 2010
Astellas Announces Changes to Director Nominees for Election to OSI Pharmaceuticals' Board of Directors(pdf49 KB)
- March 19, 2010
Astellas Announces Expiration of HSR Waiting Period for OSI Tender Offer(pdf62 KB)
- March 17, 2010
Astellas Announces Full Slate of Independent Director Nominees for Election at OSIPharmaceuticals'
2010 Annual Stockholders Meeting(pdf65 KB)
- March 16, 2010
Astellas Responds to OSI Pharmaceuticals' Rejection(pdf44 KB)
- March 3, 2010
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash Astellas Files Lawsuit Against OSI (pdf49 KB)
- March 1, 2010
Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash(pdf82 KB)
- March 1, 2010
Astellas to Send Additional Relief Effort following Haiti Earthquake
February
- February 26, 2010
Withdrawn application for approval of additional indication for type 2 diabetic incipient nephropathy for "Micardis®Tablets", Angiotensin II receptor blocker
- February 24, 2010
Entered into Global Partnership with Basilea for an Azole Antifungal Agent Isavuconazole